MedPath

The efficacy of azithromycin eye drops on the findings around the eyelids of patients with blepharitis

Not Applicable
Conditions
blepharitis
Registration Number
JPRN-UMIN000044348
Lead Sponsor
Shimazaki eye clinic/Tokyo Dental College Ichikawa General Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who understands the contents of the consent document and is able to consent in the document of the person. 2. Age of 20 years or older. 3. Patients who were defined as bacterial blepharitis at the administration start date, and with a score of 1 or more of eyelid redness/eyelid margin redness. 4. Patient who are judged to be needed to administration of azithromycin eye drops for treatment of blepharitis with MGD symptoms. 5. Patients who have all symptoms and findings shown below. Subjective symptoms Abnormal findings around openings of meibomian glands Plugging of meibomian glands 6. Patients who are judged to have symptoms of hypersecretory type MGD. 1. Patients with suspected fungal, viral, or Acanthamoeba. 2. Patients with suspected allergic conjunctivitis. 3. History of recurrent corneal erosion. 4. Any corneal epithelial loss, specifically any corneal ulcer (except for superficial punctate keratitis). 5. Patients who need to use any antibiotic, anti-inflammatory drug, vasoconstrictors, antihistamine, anti-allergic drug, disinfectant, proteolytic enzyme, herbal medicine (systemic topical, or dermally around eyelid), or treatment for MGD symptom (warm compress or lid hygiene) during the study. 6. Patients who will change the therapeutic medication for dry eye during the study. 7. Use of any corticosteroid, nonsteroidal anti-inflammatory drug, immunosuppressant (systemic, topical, or dermally around eyelid) within 1 week of enrollment. 8. Patients use Azimycin 1% eye drops within the past 45 days. 9. History of eye lid surgery within the past 90 days. 10. Known hypersensitivity or adverse effect to azithromycin, other macrolides, or to any of the drug ingredients in the study medications. 11. Participation in any other clinical study within the past 90 days or planning to participation in other clinical studies. 12. In addition, patients who are judged to have a problem to join this study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath